Physician profile
V Reddy
NPI 1588858815
$14,490.86
in general payments reported to CMS, 2019-2025
25 companies · $1,047 in 2025
The $1,047 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,888 · 2020: $805 · 2021: $2,090 · 2022: $3,690 · 2023: $3,186 · 2024: $1,785 · 2025: $1,047.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,319 · Travel and Lodging: $2,563 · Education: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,318.94 |
| Travel and Lodging | $2,562.83 |
| Education | $136.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,277.56 | 2019-2025 | Diamondback Peripheral, Supera, Proclaim |
| Medtronic, INC. | $2,396.57 | 2021-2025 | Corevalve Evolut R |
| Boehringer Ingelheim Pharmaceuticals, INC. | $771.77 | 2019-2025 | Jardiance |
| Bard Peripheral Vascular, INC. | $715.51 | 2024 | Rotarexs 6 F X 135 Cm |
| Boston Scientific Corporation | $664.64 | 2019-2025 | Watchman Access System, Ingevity+ |
| Astrazeneca Pharmaceuticals LP | $548.48 | 2019-2024 | Farxiga |
| Biosense Webster, INC. | $516.27 | 2019-2021 | |
| Impulse Dynamics (USA) INC. | $479.40 | 2021-2023 | Optimizer |
| Biotronik INC. | $423.97 | 2021-2023 | Biomonitor |
| E.R. Squibb & Sons, L.L.C. | $397.65 | 2019-2025 | Camzyos |
| Janssen Pharmaceuticals, INC | $396.96 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $360.48 | 2019-2025 | |
| Amgen INC. | $340.04 | 2021-2023 | Repatha |
| Penumbra, INC. | $306.56 | 2022-2023 | Indigo System |
| Pfizer INC. | $299.52 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $292.18 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $284.22 | 2022-2025 | Verquvo, Belsomra, Bridion |
| Novo Nordisk INC | $241.10 | 2022-2025 | Wegovy |
| Kowa Pharmaceuticals America, INC. | $215.32 | 2019-2022 | |
| Medtronic USA, INC. | $141.89 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $124.96 | 2024 | Inpefa |
| Sanofi-Aventis U.S. LLC | $124.28 | 2021 | |
| Vifor Pharma, INC. | $124.17 | 2019-2023 | Veltassa |
| Cardiovascular Systems INC. | $23.73 | 2021 | |
| Philips North America LLC | $23.63 | 2025 | Igt Devices Undivided |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw V Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.